If this box remains here for more than 30 seconds, click this link to try again.
Products & Services »
Best Practice Database
Clinical Operations » Clinical Trial Investigators
Single User: Authorizes use by the person who places the order or for whom the order was placed.
Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.
Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.
As pressure builds for pharmaceutical companies and contract research organizations (CROs) to conduct clinical trials as efficiently as possible, the importance of having an effective process of recruiting investigators becomes paramount. Pharmaceutical and CRO executives will benefit from this 22-page document by learning how to: Manage Pareto Effects and Performance Structures; Build Structures that Support Excellence; Define Roles and Responsibilities; Use Therapeutic Structures to Nurture Expertise; and Set Goals and Manage Performance.
Sample Best Practices
1.Therapeutically align employees who interact with investigative sites to cultivate scientific expertise and increase credibility with site staff.
- At one benchmark partner, monitors are therapeutically aligned by one primary area but are cross-trained in other areas.
2.Designate clear points of contact to increase credibility and responsiveness to investigators and other site staff.
- One CRO has its monitors work with one sponsor and one study at a time to improve the depth and quality of their relationships with sponsors and study sites.
3.Communicate internally to ensure people who contact investigators have a full view of all activities in place with that physician.
- Leaders at one benchmark company recommend designing a communication plan aimed at showing a united and coordinated team approach.
This research originated from a Best Practices, LLC consulting project. It was conducted for a pharmaceutical client and was based on interviews and surveys with pharmaceutical, CRO and investigator benchmark partners.